We at SOLA Diagnostics are pleased to announce that the National Institute for Health Research (NIHR) has awarded us a £2 million grant to facilitate the path to UK NHS implementation of our innovative WID®-easy Test for womb cancer.
Womb cancer, also referred to as endometrial or uterine cancer, ranks as the fourth most prevalent cancer among women in the UK and is one of the very few cancers for which mortality is still rising. The WID®-easy Test, a transformational product from SOLA Diagnostics, offers a less invasive and more accurate alternative to the current transvaginal ultrasound examination, helping reduce unnecessary tests and delays in diagnosis.
“The WID®-easy Test is a first in the UK, employing a straightforward swab method to detect womb cancer,” stated Prof Martin Widschwendter, who led the invention and development of the test. “It holds the potential to expedite the diagnosis process and could assist a larger number of women in ruling out womb cancer much earlier, circumventing prolonged waits and uncomfortable tests.”
“We’re delighted to have the NIHR’s support for implementing the WID®-easy Test,” said Dr Sara Sleigh, Head of Clinical Development at SOLA. “We’re also deeply grateful to the NCL Cancer Alliance, UCLPartners, the Eve Appeal, and the wider team for helping us reach this milestone. Their collective support will enable us to move quickly and make a meaningful difference for women across the UK.”
This groundbreaking test has great potential to make a significant impact on the womb cancer detection pathway, alleviating the burden on the NHS and enhancing patient outcomes. The substantial investment from NIHR underscores the anticipated impact of the WID®-easy Test on the future landscape of womb cancer care.